637 related articles for article (PubMed ID: 18840641)
1. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
2. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
4. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
6. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller PD; Epstein S; Sedarati F; Reginster JY
Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
[TBL] [Abstract][Full Text] [Related]
8. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
[TBL] [Abstract][Full Text] [Related]
10. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D
Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902
[TBL] [Abstract][Full Text] [Related]
11. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
12. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Stakkestad JA; Lakatos P; Lorenc R; Sedarati F; Neate C; Reginster JY
Clin Rheumatol; 2008 Aug; 27(8):955-60. PubMed ID: 18180976
[TBL] [Abstract][Full Text] [Related]
13. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
[TBL] [Abstract][Full Text] [Related]
15. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
16. The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.
Beck TJ; Fuerst T; Gaither KW; Sutradhar S; Levine AB; Hines T; Yu CR; Williams R; Mirkin S; Chines AA
Bone; 2015 Aug; 77():115-9. PubMed ID: 25917574
[TBL] [Abstract][Full Text] [Related]
17. Effect of monthly ibandronate on hip structural geometry in men with low bone density.
Genant HK; Lewiecki EM; Fuerst T; Fries M
Osteoporos Int; 2012 Jan; 23(1):257-65. PubMed ID: 21811866
[TBL] [Abstract][Full Text] [Related]
18. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
19. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
